Mutagenic potential of anti-herpes agents
- 20 January 1986
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 38 (3) , 281-289
- https://doi.org/10.1016/0024-3205(86)90314-0
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- ANTIVIRAL THERAPY: Respiratory Infections, Genital Herpes, and Herpetic KeratitisThe Lancet, 1984
- ANTIVIRAL THERAPY Varicella-zoster Virus Infections, Herpes Labialis and Mucocutaneous Herpes, and Cytomegalovirus InfectionsThe Lancet, 1984
- Antiherpes drugs: Promises and pitfallsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984
- Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replicationAntimicrobial Agents and Chemotherapy, 1984
- Treatment of Herpesvirus InfectionsNew England Journal of Medicine, 1983
- Treatment of Herpesvirus InfectionsNew England Journal of Medicine, 1983
- Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitroAntimicrobial Agents and Chemotherapy, 1983
- Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanineAntimicrobial Agents and Chemotherapy, 1983
- Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG)Biochemical and Biophysical Research Communications, 1982
- A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2Antimicrobial Agents and Chemotherapy, 1982